Navigation Links
ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
Date:1/14/2010

PHILADELPHIA, Jan. 14 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a leading provider of centralized services to the biopharmaceutical, medical device and related industries, today announced its new ERT Knowledge Series of educational papers, written by ERT experts. Each paper discusses issues relevant to patient safety in clinical trials today and further establishes ERT as an experienced and reliable partner in products and services for the clinical trials industry. The papers are now available to download from the company's website - www.ERT.com.

This new Knowledge Series of papers focuses on two of ERT's most innovative patient safety solutions, the centralized collection and analysis of ECG data to ensure cardiac safety in clinical trials and the use of electronic patient reported outcomes (ePRO) for suicidality monitoring in clinical trials. ERT's proven cardiac safety solutions offer a centralized method of accurate ECG data collection and analysis. Its centralized core laboratory enables the real-time collection of consistent and reliable ECG data -- a critical element in the accurate assessment of the cardiac effect of new drugs. Centralization not only minimizes inconsistencies that may occur from site to site but also reduces clients' workloads. ERT simplifies ECG data management and analysis to provide on-demand, real-time access to ECG study data.

Clinical trials can be delayed due to slow enrollment, problems with paper documentation and the inability to monitor sensitive patient data, costing sponsors millions of dollars. ERT's ePRO solutions enable clients to capture sensitive findings directly from their patients, a process that is critical to proving the efficacy of their compound and its effects on patient safety. ERT offers a quick and easy, phone-based, voice-response solution, which is designed and optimized to help its clients collect clinically valid and sensitive data directly from participating patients. 

John Blakeley, Executive Vice President of ERT, comments, "We are pleased to be able to offer these informative papers to the scientific community as part of the new ERT Knowledge Series. We intend to expand upon these in the future, adding more innovative papers to the series on hot industry topics and sharing our expert knowledge on products and services for clinical trials."  

Jeffrey Litwin's paper on ECG centralization examines how central core laboratories are playing an increasingly important role in cardiac safety during clinical trials. In recent years, cardiac safety concerns have been cited as the most frequent reason for many new drugs and compounds being withdrawn from the market or receiving a refusal of regulatory approval. This paper demonstrates the importance of rigorous and accurate ECG data collection and analysis during clinical trials, discussing the benefits of a centralized approach to ECG collection.      

A second paper, entitled, "Is Centralization the Future for Cardiac Safety in Clinical Trials?", authored by Amy Furlong, looks at the importance of accurate and reliable ECG data collection and analysis. This paper expands on Jeffrey Litwin's paper to look at the future of cardiac safety in clinical trials. It covers the difficulty of estimating the true costs of cardiac safety, arguing the improved accuracy of digitally generated ECG data makes the centralized approach a more cost-effective option by reducing the need for retesting. It also discusses the need for innovative new instruments and the benefits gained by the introduction of highly compact ECG systems.      

The third paper in the series, written by Michael Federico, investigates the increased risk of suicidal behaviors in patients as a result of medications. The paper examines how ePRO plays an increasingly important role in suicidality monitoring in clinical trials. It contrasts traditional face-to-face and paper-based methods of suicidality monitoring with electronic initiatives.

As part of ERT's new Knowledge Series, a complimentary webinar entitled Cardiac Safety: Best Science, Best Value will be held on Wednesday, 3 February, at 10:00 AM EST (3:00 PM GMT) and Thursday, 4 February, at 2:00 PM EST (7:00 PM GMT).  This webinar will discuss the paradigm shift taking place in the balance between science and cost in the area of cardiac safety. This webinar aims to demonstrate this new shift providing sponsors with better science while at the same time helping sponsors to maintain or even reduce costs. For additional information and to register for either of these dates, please visit www.ERT.com

For further information on ERT and its technology and services, please email info@ERT.com, call +1 215 972 0420 or visit www.ERT.com.

For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email ert@scottpr.co.uk

About ERT

Based in Philadelphia, PA ERT (eResearchTechnology, Inc.) (www.ERT.com) is a global provider of technology and services to the biopharmaceutical, medical device, and related industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE ERT

RELATED LINKS
http://www.ert.com

'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
2. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
3. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
4. European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis
5. MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009
6. Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
7. Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting
8. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
9. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
10. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
11. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)... 2017  The China and Canada joint ... less water, energy and detergent, and features a powerful disinfection process. ... shoebox-sized washing machine that washes and sanitizes women,s panties or babies, ... ... and does not require an external water inlet. ...
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
Breaking Medicine Technology:
(Date:5/28/2017)... ... 28, 2017 , ... Florida Pain Relief Group, a division ... M.D., has joined its new Melbourne pain clinic. , Dr. Fernandez-Silva’s practice ... techniques to treat and manage many types of pain. , Dr. Fernandez-Silva ...
(Date:5/27/2017)... ... May 27, 2017 , ... In any business, follow ... the talent of your dental team at presenting treatment, there will always be some ... lot of time and money on best practices when it comes to presenting treatment. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... SARASOTA, Fla. (PRWEB) , ... May 26, 2017 ... ... providers of premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining ... to your menus. , “Boar’s Head fresh sliced meats and cheeses featured ...
(Date:5/26/2017)... ... 2017 , ... Silver Birch of Hammond, a new assisted lifestyle community, has ... acres of land at 5620 Sohl Avenue in Hammond, serves older adults who need ... studio and one-bedroom apartments. Each of the private apartments at Silver Birch features a ...
Breaking Medicine News(10 mins):